Peripheral T-Cell Lymphoma
Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Published in Healthcare Finance, Tax and Law Weekly, May 7th, 2008
"The completion of enrollment in our pivotal PROPEL trial, a quarter ahead of schedule, is an important milestone for PDX and Allos," said Pablo J. Cagnoni, M.D., Chief Medical Officer of Allos. "We gratefully acknowledge the investigators and patients for participating in the study and for their important role in helping to evaluate the safety and efficacy of PDX for the treatment of relapsed or refractory peripheral T-cell lymphoma, a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
More Articles from Healthcare Finance, Tax and Law Weekly
- Abbott
Abbott to Present at Morgan Stanley Global Healthcare Unplugged Conference - Addiction Medicine
Data on addiction medicine reported by D.A. Baltieri and co-researchers - Adverse Drug Reactions
Herbalife Responds to Spain's Ministry of Health Alert - Antisocial Behavior
Studies from State University of New York further understanding of antisocial behavior - Ascendant Solutions, Inc.
Ascendant Solutions Announces the Sale of Medicine Man Pharmacies - Axela Inc.
Axela Inc. Elects Michael Treble as Chairman, Board of Directors - More from this issue of Healthcare Finance, Tax and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
